Abstract
DNA hypermethylation of CpG islands in the promoter region of genes is associated with transcriptional silencing. Treatment with hypo-methylating agents can lead to expression of these silenced genes. However, whether inhibition of DNA methylation influences the expression of unmethylated genes has not been extensively studied. We analysed the methylation status of CDKN2A and CDKN2D in human lung cancer cell lines and demonstrated that the CDKN2A CpG island is methylated, whereas CDKN2D is unmethylated. Treatment of cells with 5-aza-2′-deoxycytidine (5-Aza-CdR), an inhibitor of DNA methyltransferase 1, induced a dose and duration dependent increased expression of both p16INK4a and p19INK4d, the products of CDKN2A and CDKN2D, respectively. These data indicate that global DNA demethylation not only influences the expression of methylated genes but also of unmethylated genes. Histone acetylation is linked to methylation induced transcriptional silencing. Depsipeptide, an inhibitor of histone deacetylase, acts synergistically with 5-Aza-CdR in inducing expression of p16INK4a and p19INK4d. However, when cells were treated with higher concentrations of 5-Aza-CdR and depsipeptide, p16INK4a expression was decreased together with significant suppression of cell growth. Interestingly, p19INK4d expression was enhanced even more by the higher concentrations of 5-Aza-CdR and depsipeptide. Our data suggest that p19INK4d plays a distinct role from other INK4 family members in response to the cytotoxicity induced by inhibition of DNA methylation and histone deacetylation.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Abbreviations
- 5-Aza-CdR:
-
5-aza-2′-deoxycytidine
- DNMT:
-
DNA Methyltransferase
- HDAC:
-
Histone deacetylase
- MBP:
-
Methyl-CpG binding proteins
References
Alland L, Muhle R, Hou Jr H, Potes J, Chin L, Schreiber-Agus N, DePinho RA . 1997 Nature 387: 49–55
Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP . 1998 Adv. Cancer Res. 72: 141–196
Bell AC, Felsenfeld G . 2000 Nature 405: 482–485
Bird AP, Wolffe AP . 1999 Cell 99: 451–454
Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB . 1999 Nat. Genet. 21: 103–107
Chan MF, Liang G, Jones PA . 2000 Curr. Top. Microbiol. Immunol. 249: 75–86
Costello JF, Fruhwald MC, Smiraglia DJ, Rush LJ, Robertson GP, Gao X, Wright FA, Feramisco JD, Peltomaki P, Lang JC, Schuller DE, Yu L, Bloomfield CD, Caligiuri MA, Yates A, Nishikawa R, Su Huang H, Petrelli NJ, Zhang X, O'Dorisio MS, Held WA, Cavenee WK, Plass C . 2000 Nat. Genet. 24: 132–138
Costello JF, Plass C . 2001 J. Med. Genet. 38: 285–303
Cross SH, Charlton JA, Nan X, Bird AP . 1994 Nat. Genet. 6: 236–244
Eden S, Hashimshony T, Keshet I, Cedar H, Thorne AW . 1998 Nature 394: 842
Elson DA, Bartolomei MS . 1997 Mol. Cell. Biol. 17: 309–317
Evron E, Umbricht CB, Korz D, Raman V, Loeb DM, Niranjan B, Buluwela L, Weitzman SA, Marks J, Sukumar S . 2001 Cancer Res. 61: 2782–2787
Fuks F, Burgers WA, Brehm A, Hughes-Davies L, Kouzarides T . 2000 Nat. Genet. 24: 88–91
Gardiner-Garden M, Frommer M . 1987 J. Mol. Biol. 196: 261–282
Garrick D, Fiering S, Martin DI, Whitelaw E . 1998 Nat. Genet. 18: 56–59
Glenn CC, Saitoh S, Jong MT, Filbrandt MM, Surti U, Driscoll DJ, Nicholls RD . 1996 Am. J. Hum. Genet. 58: 335–346
Gonzalgo ML, Hayashida T, Bender CM, Pao MM, Tsai YC, Gonzales FA, Nguyen HD, Nguyen TT, Jones PA . 1998 Cancer Res. 58: 1245–1252
Graff JR, Herman JG, Myohanen S, Baylin SB, Vertino PM . 1997 J. Biol. Chem. 272: 22322–22329
Guan KL, Jenkins CW, Li Y, O'Keefe CL, Noh S, Wu X, Zariwala M, Matera AG, Xiong Y . 1996 Mol. Biol. Cell 7: 57–70
Hark AT, Schoenherr CJ, Katz DJ, Ingram RS, Levorse JM, Tilghman SM . 2000 Nature 405: 486–489
Hendrich B, Bird A . 2000 Curr. Top. Microbiol. Immunol. 249: 55–74
Herman JG, Baylin SB . 2000 Curr. Top. Microbiol. Immunol. 249: 35–54
Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB . 1996a Proc. Natl. Acad. Sci. USA 93: 9821–9826
Herman JG, Jen J, Merlo A, Baylin SB . 1996b Cancer Res. 56: 722–727
Herman JG, Merlo A, Mao L, Lapidus RG, Issa JP, Davidson NE, Sidransky D, Baylin SB . 1995 Cancer Res. 55: 4525–4530
Issa JP, Vertino PM, Wu J, Sazawal S, Celano P, Nelkin BD, Hamilton SR, Baylin SB . 1993 J. Natl. Cancer Inst. 85: 1235–1240
Juttermann R, Li E, Jaenisch R . 1994 Proc. Natl. Acad. Sci. USA 91: 11797–11801
Jones PA, Laird PW . 1999 Nat. Genet. 21: 163–167
Knudsen S . 1999 Bioinformatics 15: 356–361
Kumari D, Usdin K . 2000 J. Biol. Chem. 31: 31
Li E, Beard C, Jaenisch R . 1993 Nature 366: 362–365
Li E, Bestor TH, Jaenisch R . 1992 Cell 69: 915–926
Loeb DM, Evron E, Patel CB, Sharma PM, Niranjan B, Buluwela L, Weitzman SA, Korz D, Sukumar S . 2001 Cancer Res. 61: 921–925
Nan X, Ng HH, Johnson CA, Laherty CD, Turner BM, Eisenman RN, Bird A . 1998 Nature 393: 386–389
Ng HH, Bird A . 1999 Curr. Opin. Genet. Dev. 9: 158–163
Ohler U, Stemmer G, Harbeck S, Niemann H . 2000 Pac. Symp. Biocomput 380–391
Okuda T, Hirai H, Valentine VA, Shurtleff SA, Kidd VJ, Lahti JM, Sherr CJ, Downing JR . 1995 Genomics 29: 623–630
Otterson GA, Khleif SN, Chen W, Coxon AB, Kaye FJ . 1995 Oncogene 11: 1211–1216
Pfeifer GP, Tanguay RL, Steigerwald SD, Riggs AD . 1990 Genes Dev. 4: 1277–1287
Prestridge DS . 1995 J. Mol. Biol. 249: 923–932
Robertson KD, Ait-Si-Ali S, Yokochi T, Wade PA, Jones PL, Wolffe AP . 2000 Nat. Genet. 25: 338–342
Robertson KD, Jones PA . 2000 Carcinogenesis 21: 461–467
Robertson KD, Uzvolgyi E, Liang G, Talmadge C, Sumegi J, Gonzales FA, Jones PA . 1999 Nucleic Acids Res. 27: 2291–2298
Rountree MR, Bachman KE, Baylin SB . 2000 Nat. Genet. 25: 269–277
Soengas MS, Alarcon RM, Yoshida H, Giaccia AJ, Hakem R, Mak TW, Lowe SW . 1999 Science 284: 156–159
Soengas MS, Capodieci P, Polsky D, Mora J, Esteller M, Opitz-Araya X, McCombie R, Herman JG, Gerald WL, Lazebnik YA, Cordon-Cardo C, Lowe SW . 2001 Nature 409: 207–211
Staiger D, Kaulen H, Schell J . 1989 Proc. Natl. Acad. Sci. USA 86: 6930–6934
Tate PH, Bird AP . 1993 Curr. Opin. Genet. Dev. 3: 226–231
Tycko B . 2000 J. Clin. Invest. 105: 401–407
Yoo-Warren H, Pachnis V, Ingram RS, Tilghman SM . 1988 Mol. Cell. Biol. 8: 4707–4715
Zhu WG, Lakshmanan RR, Beal MD, Otterson GA . 2001 Cancer Res. 61: 1327–1333
Acknowledgements
We thank Drs Yue Xiong and Xin-Hai Pei for kindly providing us information about the putative promoter region of human CDKN2D. We also thank Drs Lawrence Druhan and Melissa Hunter for their technical assistance, and Dr Michael Grever for the gift of depsipeptide. This work is supported in part by grants from the American Cancer Society, Ohio Division, Ohio Cancer Research Associates and by grant P30 CA16058, National Cancer Institute, Bethesda, MD, USA.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Zhu, WG., Dai, Z., Ding, H. et al. Increased expression of unmethylated CDKN2D by 5-aza-2′-deoxycytidine in human lung cancer cells. Oncogene 20, 7787–7796 (2001). https://doi.org/10.1038/sj.onc.1204970
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1204970
Keywords
This article is cited by
-
Gestational oral low-dose estradiol-17β induces altered DNA methylation of CDKN2D and PSAT1 in embryos and adult offspring
Scientific Reports (2018)
-
5-azacytidine affects TET2 and histone transcription and reshapes morphology of human skin fibroblasts
Scientific Reports (2016)
-
DNA promoter and histone H3 methylation downregulate NGX6 in gastric cancer cells
Medical Oncology (2014)
-
Pharmacokinetic and pharmacodynamic analysis of 5-aza-2’-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy
Clinical Epigenetics (2013)
-
The pituitary tumour epigenome: aberrations and prospects for targeted therapy
Nature Reviews Endocrinology (2012)